Breaking News

An AI experiment at the FDA & Novo trailing in the obesity drug race

June 6, 2025

On this week's episode of "The Readout LOUD": The Food and Drug Administration's AI adventure, a deep look inside Novo Nordisk's obesity stumble, and finally, another big M&A deal in biotech.

The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can't seem to let go of mistakes. Our colleague Brittany Trang joins to explain. And it's always a fun podcast when we can discuss a biotech acquisition. This week, we'll chat about Sanofi's $9 billion offer for Blueprint Medicines.

But first, Novo Nordisk was once the leader in the obesity drug race. Today, it trails Eli Lilly. Our co-host Elaine Chen has a new story published this week that examines the reasons behind Novo's fall and what it's doing to catch up. You'll hear all about it. 

Listen Now

Subscribe to the podcast on Apple Podcasts or Spotify to never miss an episode

Visit the archive to see past episodes 



Enjoying The Readout LOUD? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments